Armenta was established to address the most pressing disease affecting dairy farming today: Bovine Mastitis.
Losses due to bovine mastitis can reach several billion dollars per year. Armenta developed innovative non-invasive; antibiotics free therapies based on acoustic pulse technology (APT). APT has been used for over 20 years in human healthcare treating inflammatory diseases. Armenta employs experts in acoustic pulse treatment and engineering, mastitis researchers, ex-dairy farmers and dairy farming operation, bringing their skills and proficiency into developing the optimal solutions for bovine mastitis.
To that end, the company developed an innovative, non-invasive and antibiotics-free therapy that has proven to increase milk yield and quality, as well as reduce culling, using acoustic pulse technology (APT).
The continuous use of antibiotics plays a role in weakening the cows’ immune system making them more susceptible to repeated infections and therefore impacting the overall animal welfare and the ability to produce milk in quantities that are profitable enough for the farmer to keep the cow in the herd. Implementing APT reduces the need for antibiotics, contributing to stronger, healthier and more productive cows.
Using APT, the monetary losses the dairy farmer currently has due to mastitis will drop. In addition immediate increase in income from milk production, as the cow is healed from the disease, but also over time and throughout the lactation period, making APT a necessary tool to make dairy farming more profitable.
Evolving consumer buying habits, growing consumers' concerns regarding health, the environment, and animal welfare, alongside their willingness to pay a premium price for healthy food, are all variables fueling the demand for high quality and safe dairy products hence requires the development of alternative treatments of mastitis as the highest impact of the use of antibiotics is shown on the milk quality, safety and quantity.
Bridging the AMR Gap
The use of antibiotics in the treatment and prevention of bovine mastitis is becoming more and more burdensome. The results are unsatisfactory, it undermines farm profitability, and it directly contributes to anti-microbial resistance (AMR). Growing awareness of the human health risks posed by AMR is triggering global restrictions on the use of antibiotics among livestock.
Armenta steps into that gap with the only technology that effectively treats mastitis without the use of antibiotics.
Armenta has joined the front lines of the Antimicrobial Resistance (AMR) Challenge, a US initiative launched at the United Nations to encourage governments, companies, and NGOs worldwide to collaborate against antimicrobial resistance. Armenta supports the AMR Challenge’s “One Health” approach, recognizing the link between the health of people, animals and the environment, reflected in our ongoing development of novel treatments for the most pervasive dairy cattle diseases.
Chairman & CEO
Gil has over 20 years of experience in executive positions in multinational med-tech, biotech and pharma industry companies. He served previously as the CEO and...
Gil has over 20 years of experience in executive positions in multinational med-tech, biotech and pharma industry companies. He served previously as the CEO and then president of UroGen Pharma (NASDAQ: URGN). Prior to that, Gil was the Director of New Product Development at Medispec Ltd., leading the research and development of novel medical devices using low intensity shockwaves to treat ischemic and inflammatory diseases. These products are currently in use worldwide.
Founder & CTO
Eddie has over 20 years of experience in translating concepts into engineering, and developing working products, especially in the field of shockwave-based technologies. Drawing on...
Eddie has over 20 years of experience in translating concepts into engineering, and developing working products, especially in the field of shockwave-based technologies. Drawing on his experience as a former Israeli champion in air-rifle marksmanship, Eddie designed and patented a completely novel method to produce shockwaves using the operating principles of an air rifle
Prof. Gabriel Leitner
Gabriel has 25 years of experience researching udder diseases, immunological responses, and the interactions between them. He has written over 130 articles in peer-reviewed journals,...
Gabriel has 25 years of experience researching udder diseases, immunological responses, and the interactions between them. He has written over 130 articles in peer-reviewed journals, 11 books, book chapters, reviews, and articles, as well as delivering over 160 lectures published in symposia proceedings. Gabriel is also a member of the Israel Cattle Breeders Association, the Israel Sheep and Goat Breeders Association, the Scientific Committee of the Kimron Veterinary Institute in Israel, and the Israel Dairy Board. Since 2011, he has been a member of the International Dairy Federation’s (IDF) Standing Committee on Animal Health (SCAH) and the Committee on Mastitis (AT-AH-01). Gabriel received his PhD in Immunology from Hebrew University and completed postdoctoral work at the University of Minnesota.